Reduced renal methylarginine metabolism protects against progressive kidney damage

Journal of the American Society of Nephrology

Volumn 26, Issue 12, 2015, Pages 3045-3059

  Tomlinson, James A P ^a   Caplin, Ben ^b   Boruc, Olga ^a   Bruce Cobbold, Claire ^a   Cutillas, Pedro ^a   Dormann, Dirk ^a   Faull, Peter ^a   Grossman, Rebecca C ^b   Khadayate, Sanjay ^a   Mas, Valeria R ^c   Nitsch, Dorothea D ^d   Wang, Zhen ^a   Norman, Jill T ^b   Wilcox, Christopher S ^e   Wheeler, David C ^b   Leiper, James ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY OF VIRGINIA   (United States)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIMETHYLARGININASE; DIMETHYLARGININE DIMETHYLAMINOHYDROLASE 1; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; UNCLASSIFIED DRUG; ALANINE-GLYOXYLATE TRANSAMINASE; AMIDASE; AMINOTRANSFERASE; ARGININE; COLLAGEN TYPE 1; COLLAGEN TYPE I, ALPHA 1 CHAIN; FOLIC ACID; MESSENGER RNA; N,N-DIMETHYLARGININE; TAMM HORSFALL GLYCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; DISEASE ASSOCIATION; ELECTROLYTE URINE LEVEL; FOLATE NEPHROPATHY; GENE EXPRESSION; GENE TARGETING; GENETIC VARIABILITY; GLOMERULUS CAPILLARY; HUMAN; HUMAN TISSUE; KIDNEY ALLOGRAFT; KIDNEY GRAFT; KIDNEY INJURY; KIDNEY METABOLISM; KIDNEY TUBULE CELL; MAGNETIC SEPARATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; RENAL PROTECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UNILATERAL URETERIC OBSTRUCTION NEPHROPATHY; URETER OBSTRUCTION; ACUTE KIDNEY INJURY; ADULT; ALLOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; COMPLICATION; ENZYMOLOGY; FEMALE; GENETICS; GLOMERULUS FILTRATION RATE; KIDNEY PROXIMAL TUBULE; KIDNEY TRANSPLANTATION; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; TRANSGENIC MOUSE; URINE;

ACUTE KIDNEY INJURY; ADULT; ALLOGRAFTS; AMIDOHYDROLASES; ANIMALS; ARGININE; COLLAGEN TYPE I; FEMALE; FOLIC ACID; GENE EXPRESSION; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY TRANSPLANTATION; KIDNEY TUBULES, PROXIMAL; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MIDDLE AGED; NITRIC OXIDE; RNA, MESSENGER; TRANSAMINASES; URETERAL OBSTRUCTION; UROMODULIN;

EID: 84958243960     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2014030280     Document Type: Article

References (51)

1. Jha V, Wang AY, Wang H: The impact of CKD identification in large countries: the burden of illness. Nephrol Dial Transplant 27[Suppl 3]: iii32-iii38, 2012
2. World Health Organization: Global status report on noncommunicable diseases 2010. 2011. Available at: http://www.who.int/nmh/publications/ncd-report2010/en/. Accessed July 7, 2013
3. Baylis C: Nitric oxide synthase derangements and hypertension in kidney disease. Curr Opin Nephrol Hypertens 21: 1-6, 2012
4. Moncada S, Palmer RM, Higgs EA: Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 43: 109-142, 1991
5. Caplin B, Wang Z, Slaviero A,Tomlinson J, Dowsett L, Delahaye M, Salama A, International Consortium for Blood Pressure Genome-Wide Association Studies, Wheeler DC, Leiper J: Alanine-glyoxylate aminotransferase-2 metabolizes endogenousmethylarginines, regulatesNO, and controls blood pressure. Arterioscler Thromb Vasc Biol 32: 2892-2900, 2012
6. Caplin B, Leiper J: Endogenous nitric oxide synthase inhibitors in the biology of disease: Markers, mediators, and regulators? Arterioscler Thromb Vasc Biol 32(6): 1343-1353, 2012
7. OnozatoML, Tojo A, Leiper J, Fujita T, PalmF, Wilcox CS: Expression of NG,NG-dimethylarginine dimethylaminohydrolase and protein arginine N-methyltransferase isoforms in diabetic rat kidney: Effects of angiotensin II receptor blockers. Diabetes 57: 172-180, 2008
8. Mount PF, Power DA: Nitric oxide in the kidney: Functions and regulation of synthesis. Acta Physiol (Oxf) 187: 433-446, 2006
9. Majid DS, Navar LG: Nitric oxide in the control of renal hemodynamics and excretory function. Am J Hypertens 14: 74S-82S, 2001
10. Carlström M, Lai EY, Ma Z, Steege A, Patzak A, Eriksson UJ, Lundberg JO, Wilcox CS, Persson AE: Superoxide dismutase 1 limits renal microvascular remodeling and attenuates arteriole and blood pressure responses to angiotensin II viamodulation of nitric oxide bioavailability. Hypertension 56: 907-913, 2010
11. Wilcox CS: Role of macula densa NOS in tubuloglomerular feedback. Curr Opin Nephrol Hypertens 7: 443-449, 1998
12. Ortiz PA, Garvin JL: Role of nitric oxide in the regulation of nephron transport. Am J Physiol Renal Physiol 282: F777-F784, 2002
13. Tojo A,WelchWJ, Bremer V, KimotoM, Kimura K, OmataM,Ogawa T, Vallance P, Wilcox CS: Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney. Kidney Int 52: 1593-1601, 1997
14. Nijveldt RJ, Van Leeuwen PA, Van Guldener C, Stehouwer CD, Rauwerda JA, Teerlink T: Net renal extraction of asymmetrical (ADMA) and symmetrical (SDMA) dimethylarginine in fasting humans. Nephrol Dial Transplant 17: 1999-2002, 2002
15. Vallance P, Leone A, Calver A, Collier J,Moncada S: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339: 572-575, 1992
16. Böger RH, Sullivan LM, Schwedhelm E,Wang TJ,Maas R, Benjamin EJ, Schulze F, Xanthakis V, Benndorf RA, Vasan RS: Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 119: 1592-1600, 2009
17. Schulze F, Lenzen H, Hanefeld C, Bartling A, Osterziel KJ, Goudeva L, Schmidt-Lucke C, Kusus M, Maas R, Schwedhelm E, Strödter D, Simon BC, Mügge A, Daniel WG, Tillmanns H, Maisch B, Streichert T, Böger RH: Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMAConcentration (CARDIAC) study. Am Heart J 152: e1-e8, 2006
18. Zoccali C, Bode-Böger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frölich J, Böger R: Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358: 2113-2117, 2001
19. Young JM, Terrin N,Wang X, Greene T, Beck GJ, Kusek JW, Collins AJ, Sarnak MJ, Menon V: Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease. Clin J Am Soc Nephrol 4: 1115-1120, 2009
20. Fliser D, Kronenberg F, Kielstein JT, Morath C, Bode-Böger SM, Haller H, Ritz E: Asymmetric dimethylarginine and progression of chronic kidney disease: The mild to moderate kidney disease study. J Am Soc Nephrol 16: 2456-2461, 2005
21. Caplin B, Nitsch D, Gill H, Hoefield R, Blackwell S, MacKenzie D, Cooper JA,Middleton RJ, Talmud PJ, Veitch P,Norman J,WheelerDC, Leiper JM: Circulating methylarginine levels and the decline in renal function in patients with chronic kidney disease are modulated by DDAH1 polymorphisms. Kidney Int 77: 459-467, 2010
22. Li H, Zhou X, Davis DR, Xu D, Sigmund CD: An androgen-inducible proximal tubule-specific Cre recombinase transgenic model. Am J Physiol Renal Physiol 294: F1481-F1486, 2008
23. Leiper J, Nandi M, Torondel B, Murray-Rust J, Malaki M, O'Hara B, Rossiter S, Anthony S, Madhani M, Selwood D, Smith C, Wojciak-Stothard B, Rudiger A, Stidwill R,McDonald NQ, Vallance P: Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med 13: 198-203, 2007
24. Muller V, Tain YL, Croker B, Baylis C: Chronic nitric oxide deficiency and progression of kidney disease after renal mass reduction in the C57Bl6 mouse. Am J Nephrol 32: 575-580, 2010
25. Arcos MI, Fujihara CK, Sesso A, de Almeida Prado EB, de Almeida PradoMJ, de NucciG, Zatz R:Mechanisms of albuminuria in the chronic nitric oxide inhibition model. Am J Physiol Renal Physiol 279: F1060-F1066, 2000
26. SudaO, Tsutsui M, Morishita T, Tanimoto A, HoriuchiM, Tasaki H, Huang PL, Sasaguri Y, Yanagihara N, Nakashima Y: Long-term treatment with N (omega)-nitro-L-arginine methyl ester causes arteriosclerotic coronary lesions in endothelial nitric oxide synthase-deficient mice. Circulation 106: 1729-1735, 2002
27. Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, Zoccali C: Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: A competing risks modeling approach. J Am Soc Nephrol 16: 2449-2455, 2005
28. Mihout F, Shweke N, Bigé N, Jouanneau C, Dussaule JC, Ronco P, Chatziantoniou C, Boffa JJ: Asymmetric dimethylarginine (ADMA) induces chronic kidney disease through a mechanism involving collagen and TGF-b1 synthesis. J Pathol 223: 37-45, 2011
29. Matsumoto Y, Ueda S, Yamagishi S,Matsuguma K, Shibata R, Fukami K, Matsuoka H, Imaizumi T, Okuda S: Dimethylarginine dimethylaminohydrolase prevents progression of renal dysfunction by inhibiting loss of peritubular capillaries and tubulointerstitial fibrosis in a rat model of chronic kidney disease. J Am Soc Nephrol 18: 1525-1533, 2007
30. Jacobi J,Maas R, Cordasic N, Koch K, Schmieder RE, Böger RH, Hilgers KF: Role of asymmetric dimethylarginine for angiotensin II-induced target organ damage in mice. Am J Physiol Heart Circ Physiol 294: H1058-H1066, 2008
31. Xia W, Szomor Z, Wang Y, Murrell GA: Nitric oxide enhances collagen synthesis in cultured human tendon cells.JOrthopRes 24: 159-172, 2006
32. Thornton FJ, Schäffer MR, Witte MB, Moldawer LL, MacKay SL, Abouhamze A, Tannahill CL, Barbul A: Enhanced collagen accumulation following direct transfection of the inducible nitric oxide synthase gene in cutaneous wounds. Biochem Biophys Res Commun 246: 654-659, 1998
33. Shi HP, Efron DT, Most D, Tantry US, Barbul A: Supplemental dietary arginine enhances wound healing in normal but not inducible nitric oxide synthase knockout mice. Surgery 128: 374-378, 2000
34. Guix FX, Uribesalgo I, Coma M, Muñoz FJ: The physiology and pathophysiology of nitric oxide in the brain. Prog Neurobiol 76: 126-152, 2005
35. Chatziantoniou C, Boffa JJ, Ardaillou R, Dussaule JC: Nitric oxide inhibition induces early activation of type I collagen gene in renal resistance vessels and glomeruli in transgenic mice. Role of endothelin. J Clin Invest 101: 2780-2789, 1998
36. Peters H, BorderWA,NobleNA: L-Arginine supplementation increases mesangial cell injury and subsequent tissue fibrosis in experimental glomerulonephritis. Kidney Int 55: 2264-2273, 1999
37. Eberhardt W, Pfeilschifter J: Nitric oxide and vascular remodeling: spotlight on the kidney. Kidney Int Suppl (106, Suppl Suppl): S9-S16, 2007
38. Peters H, Border WA, Rückert M, Krämer S, Neumayer HH, Noble NA: L-arginine supplementation accelerates renal fibrosis and shortens life span in experimental lupus nephritis. Kidney Int 63: 1382-1392, 2003
39. Weinberg JB, Granger DL, Pisetsky DS, Seldin MF, Misukonis MA, Mason SN, Pippen AM, Ruiz P,Wood ER, Gilkeson GS: The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease: Increased nitric oxide production and nitric oxide synthase expression in MRL-lpr/lpr mice, and reduction of spontaneous glomerulonephritis and arthritis by orally administered NG-monomethyl-L-arginine. J ExpMed 179: 651-660, 1994
40. Pullamsetti SS, Savai R, Dumitrascu R, Dahal BK, Wilhelm J, Konigshoff M, Zakrzewicz D, Ghofrani HA, Weissmann N, Eickelberg O, Guenther A, Leiper J, Seeger W, Grimminger F, Schermuly RT: The role of dimethylarginine dimethylaminohydrolase in idiopathic pulmonary fibrosis. Sci Transl Med 3: 87ra53, 2011
41. Bachmann S, Metzger R, Bunnemann B: Tamm-Horsfall protein-mRNA synthesis is localized to the thick ascending limb of Henle's loop in rat kidney. Histochemistry 94: 517-523, 1990
42. Drenning JA, Lira VA, Simmons CG, Soltow QA, Sellman JE, Criswell DS: Nitric oxide facilitates NFAT-dependent transcription in mouse myotubes. Am J Physiol Cell Physiol 294: C1088-C1095, 2008
43. Liu XK, Abernethy DR, Andrawis NS: Nitric oxide inhibits Oct-1 DNA binding activity in cultured vascular smooth muscle cells. Life Sci 62: 739-749, 1998
44. Kim HT, Song IY, Piedrahita J: Kidney-specific activity of the bovine uromodulin promoter. Transgenic Res 12: 191-201, 2003
45. Rampoldi L, Scolari F, Amoroso A, Ghiggeri G, Devuyst O: The rediscovery of uromodulin (Tamm-Horsfall protein): From tubulointerstitial nephropathy to chronic kidney disease. Kidney Int 80: 338-347, 2011
46. TruduM, Janas S, Lanzani C, Debaix H, Schaeffer C, Ikehata M, Citterio L, Demaretz S, Trevisani F, Ristagno G, Glaudemans B, Laghmani K, Dell'AntonioG, LoffingJ, RastaldiMP,Manunta P,DevuystO,Rampoldi L, Paccaud F, Pechere-Bertschi A, Vogt B, Ackermann D, Ehret G,Guessous I, Ponte B, PruijmM, Loffing J, RastaldiMP,Manunta P, Rampoldi L; Swiss Kidney Project on Genes in Hypertension (SKIPOGH) team: Common noncoding UMOD gene variants induce salt-sensitive hypertension and kidney damage by increasing uromodulin expression. NatMed 19: 1655-1660, 2013
47. Heffner CS, Herbert Pratt C, Babiuk RP, Sharma Y, Rockwood SF, Donahue LR, Eppig JT, Murray SA: Supporting conditional mouse mutagenesis with a comprehensive cre characterization resource. Nat Commun 3: 1218, 2012
48. Buerger A, Rozhitskaya O, Sherwood MC, Dorfman AL, Bisping E, Abel ED, Pu WT, Izumo S, Jay PY: Dilated cardiomyopathy resulting from high-level myocardial expression of Cre-recombinase. J Card Fail 12: 392-398, 2006
49. Forni PE, Scuoppo C, Imayoshi I, Taulli R, Dastr W, Sala V, Betz UA, Muzzi P,Martinuzzi D, Vercelli AE, Kageyama R, Ponzetto C: High levels of Cre expression in neuronal progenitors cause defects in brain development leading to microencephaly and hydrocephaly. J Neurosci 26: 9593-9602, 2006
50. Naiche LA, Papaioannou VE: Cre activity causes widespread apoptosis and lethal anemia during embryonic development. Genesis 45: 768-775, 2007
51. Norden AG, Sharratt P, Cutillas PR, Cramer R, Gardner SC, Unwin RJ: Quantitative amino acid and proteomic analysis: Very low excretion of polypeptides.750Da in normal urine. Kidney Int 66: 1994-2003, 2004